HEALTHSTREAM ANNOUNCES SECOND QUARTER 2026 RESULTS

WJRJJ Ventures disclosed a 9.6% stake in HealthStream, acquired through open-market buys and a deal at $29.50 per share. The investment includes a one-year standstill and registration rights. WJRJJ plans to hold shares for investment but may buy or sell more over time. Willis Johnson, managing member of WJRJJ, is involved in the investment.

Humana (HUM) and HealthStream (HSTM) partnered to expand caregiver training. Humana reported Q2 2026 adjusted EPS of $7.61, lowering FY GAAP EPS guidance to $6.52. HealthStream saw Q2 revenue rise 12.5% to $83.7M, with net income up 23.8%. Humana faces regulatory pressures, while HealthStream benefits from strong margins and a debt-free balance sheet.

HealthStream Inc. (HSTM) reported Q2 profit of $6.7 million, or 23 cents per share, on revenue of $83.7 million. The company expects full-year revenue of $327 million to $332 million, according to the report.

Levi Strauss & Co. (LEVI) CEO Michelle Gass admitted the company missed the U.S. shift to low-rise jeans during the back-to-school season, impacting its direct-to-consumer sales. Despite a 4% revenue increase to $1.6 billion in Q3, shares fell nearly 5%. Levi's has since refocused marketing on low-rise styles and expects full-year revenue growth of about 6%.

Delta Air Lines (DAL) has a $95 price target from Susquehanna, implying 18% upside. Q3 revenue rose 16% YoY to $17.6B, but fuel costs cut 2026 earnings forecast to $5.10–$5.60/share. Risks include rising fuel prices, margin pressures, and geopolitical disruptions.

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.